eligibility_summary
Adults ≥18. Treatment: path-confirmed AITL with IDH2 mutation (MSK ddPCR), R/R after ≥1 therapy, measurable disease, ECOG ≤2, adequate labs, washout ≥2 wks/5 half-lives, steroids ≤25 mg pred at start, contraception, women neg pregnancy test, no breastfeeding. Exclude: allo-SCT on immunosuppression/GVHD, unresolved tox >1, chronic liver/VOD/alcohol abuse, live vaccine <6 wks, malabsorption surgery, uncontrolled HIV/HBV/HCV or active CMV, on other cancer therapy, CNS AITL, active infection, major cardiac dz/LVEF<40, prior enasidenib, problematic CYP/P-gp/BCRP/UGT1A1 meds (rosuvastatin unless switched, digoxin adjust).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in IDH2-mutant angioimmunoblastic T-cell lymphoma (AITL). Interventions: (1) Enasidenib—oral small-molecule inhibitor of mutant isocitrate dehydrogenase-2 (IDH2), lowers oncometabolite 2-hydroxyglutarate, reversing epigenetic dysregulation and promoting differentiation of malignant T cells. (2) Rituximab—IV anti-CD20 monoclonal antibody, depletes CD20+ B cells via ADCC/CDC/apoptosis, used only if co-occurring B-cell lymphoproliferation is present. Targets/pathways: mutant IDH2 metabolic/epigenetic pathway (TET/DNA demethylation axis) in AITL tumor cells, CD20+ B-cell clones in the tumor microenvironment. Goal: assess safety and activity of enasidenib ± B-cell depletion.